McKeon Andrew, Ozelius Laurie J, Hardiman Oria, Greenway Matthew J, Pittock Sean J
Department of Neurology, Beaumont Hospital Dublin and Royal College of Surgeons in Ireland, Dublin, Ireland.
Mov Disord. 2007 Jul 15;22(9):1325-7. doi: 10.1002/mds.21335.
The authors report a 7-year follow-up video study and molecular data on the Irish rapid-onset dystonia-Parkinsonism kindred. All affected patients tested had a missense mutation in the Na(+)/K(+) -ATPase alpha3 subunit (ATP1A3), twice previously identified, suggestive of a mutation hotspot. Clinical presentation, progression, and outcome in this kindred is varied. Some patients remain stable over many years, others worsen, have a fluctuating course, or improve over time. To date there have been no effective treatments for this disorder, although Na(+)/K(+) ATPase may be a future therapeutic target. The broad phenotypic spectrum of RDP described in the text and detailed in the video, should be considered when evaluating patients with dystonia.
作者报告了一项针对爱尔兰快速起病性肌张力障碍-帕金森综合征家系的7年随访视频研究及分子数据。所有接受检测的患病患者在Na(+)/K(+) -ATP酶α3亚基(ATP1A3)中均存在一个错义突变,该突变此前已被发现两次,提示存在一个突变热点。这个家系中的临床表现、病情进展及预后各不相同。一些患者多年来病情保持稳定,另一些则病情恶化、病程波动或随时间改善。迄今为止,针对这种疾病尚无有效治疗方法,不过Na(+)/K(+) ATP酶可能是未来的治疗靶点。在评估肌张力障碍患者时,应考虑本文所述及视频中详细展示的RDP广泛的表型谱。